Subject: Re: Anatomy of a Moon Shot...
https://www.esperion.com/news-...

Today's PR illustrates the ongoing adoption and improved coverage (cost and in some/most cases of not needing prior authorization from a cardiologist) that will be key to sales growth.

Similar to how improvements occurred in June at end of Q2, this improvement is occurring in Sept at end of Q3.
Q3 numbers should be decent. I am forecasting $33-35m in US sales only.

Q4 could see an inflection to the $40m range. That would be 100% y/y growth and really drive home the idea that this has now entered hyper-growth and my contention is that being viewed as a growth stock will cause a re-rating of the stock in terms of multiple/valuation.

Will see.

Dreamer